At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,392 enrolled
Drug / intervention
Esomeprazole +2 moredrug
Likely dose
Esomeprazole 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Rabeprazole and Esomeprazole Reflux Assessment Trial (TREAT)
In Brief
A Phase 4 clinical trial evaluating Esomeprazole and Rabeprazole for Gastro-oesophageal Reflux. Completed, enrolled 1,392 participants across 25 sites.
Detailed Summary
The primary objective of this study is to compare, the number of patients with heartburn and regurgitation symptom resolution after treatment with either rabeprazole 20 mg, esomeprazole 20 mg or esomeprazole 40 mg.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastro-oesophageal Reflux
CountriesAustralia
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2006
First PostedApr 2007
Primary CompletionMay 2008
TodayJul 2026
First PostedApr 23, 2007
Enrollment StartNov 1, 2006
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 19.2 years ago
Interventions
Esomeprazoledrug
20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
Rabeprazoledrug
20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
Esomeprazoledrug
40mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily